Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting-Reference-Cited by-同舟云学术

Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting

Published:2020-08-13 Issue:8 Volume:15 Page:e0237582
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yen Hsu-Heng^ORCID,Su Pei-Yuan,Zeng Ya-Huei,Liu I-Ling,Huang Siou-Ping,Hsu Yu-Chun,Chen Yang-Yuan,Yang Chia-Wei,Wu Shun-Sheng,Chou Kun-Ching

Funder

Changhua Christian Hospital

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference26 articles.

1. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment;CH Liu;J Viral Hepat,2020

2. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment;E Gane;N Engl J Med,2017

3. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy;F Ansaldi;World J Gastroenterol,2014

4. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin;PY Su;Kaohsiung J Med Sci,2016

5. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial;CH Liu;Ann Intern Med,2013

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis;Frontiers in Public Health;2023-09-29

2. Effective Machine Learning Techniques to Detect Fatty Liver Disease;2023 Second International Conference on Electronics and Renewable Systems (ICEARS);2023-03-02

3. A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD;Kidney International Reports;2023-02

4. Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease;Viruses;2022-11-20

5. A retrospective study of prevalence and pattern of international consensus on ANA patterns among patients with hepatitis C virus infection;PeerJ;2022-10-18